董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hadar Ron | 女 | Director | 64 | 未披露 | 未持股 | 2023-02-14 |
| Moshe Mizrahy | 男 | Chief Executive Officer and Chairman of Board | 70 | 21.60万美元 | 未持股 | 2023-02-14 |
| Michael Kreindel | 男 | Chief Technology Officer and Director | 56 | 21.70万美元 | 未持股 | 2023-02-14 |
| Bruce Mann | 男 | Director | 88 | 未披露 | 未持股 | 2023-02-14 |
| Michael Anghel | 男 | Director | 84 | 未披露 | 未持股 | 2023-02-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Moshe Mizrahy | 男 | Chief Executive Officer and Chairman of Board | 70 | 21.60万美元 | 未持股 | 2023-02-14 |
| Yair Malca | 男 | Chief Financial Officer | 45 | 120.10万美元 | 未持股 | 2023-02-14 |
| Michael Kreindel | 男 | Chief Technology Officer and Director | 56 | 21.70万美元 | 未持股 | 2023-02-14 |
| Shakil Lakhani | 男 | President, North America | 40 | 328.00万美元 | 未持股 | 2023-02-14 |
董事简历
中英对照 | 中文 | 英文- Hadar Ron
-
Hadar Ron于2019年8月成为InMode Ltd.公司董事。自2000年以来，Ron博士一直是以色列生命科学风险投资基金Israel Healthcare Ventures的创始和管理合伙人。Ron博士还是以色列生命科学风险投资基金Israel Healthcare Ventures 2 LPIncorporated（IHCV2）管理公司的首席执行官。Ron博士担任专门从事结肠直肠筛查的医疗器械公司G.I. View Ltd.和信息技术初创公司CyTwist Ltd.的董事长，并担任以下公司的董事会成员：Home Skinovations Ltd.、SipNose Ltd.、Pet Novations Ltd.、Peri-Ness Technologies Ltd.、Viroblock Ltd.、O.G.D.H. Ltd.、OrSense Ltd.和NanoPass Technologies Ltd.。此外，Ron博士担任Together Pharma Ltd.的外部董事。此外，Ron博士还担任Momentum Fund的艾瑞博德成员，Momentum Fund是特拉维夫大学技术转让研究中心的成员，也是Birad Ltd的董事会成员，Bar Ilan大学的技术转让公司，也是以色列社会金融协会预防糖尿病和结肠癌的社会影响债券科学顾问委员会的主席。Ron医生是一名医生和受过教育的律师。她拥有特拉维夫大学的医学博士和法学博士学位，并曾在特拉维夫大学工商管理学院学习。
Hadar Ron became a director of the Company in August 2019. Since 2000, Dr. Ron has been the founding and managing partner of Israel Healthcare Ventures, an Israeli life science venture capital fund. Dr. Ron is also the chief executive officer of the management company for Israel Healthcare Ventures 2 LP Incorporated, or IHCV2, an Israeli life sciences venture capital fund. Dr. Ron serves as chairperson of G.I. View Ltd., a medical device company specializing in colorectal screenings, and CyTwist Ltd., an information technology start-up company, and as a board member of the following companies: Home Skinovations Ltd., SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Viroblock Ltd., O.G.D.H. Ltd., OrSense Ltd., and NanoPass Technologies Ltd. In addition, Dr. Ron serves as an external director of Together Pharma Ltd. In addition, Dr. Ron serves as a member of the advisory board of the Momentum Fund Tech Transfer of Tel Aviv University, a board member of BIRAD Ltd., the tech transfer company of Bar Ilan University, and is the chairperson of the scientific advisory board of Social Finance Israel's Social Impact Bond for the prevention of diabetes and colon cancer. Dr. Ron is a physician and attorney by education. She holds M.D. and L.L.B. degrees from Tel Aviv University and has studied at the School of Business Administration at Tel Aviv University. - Hadar Ron于2019年8月成为InMode Ltd.公司董事。自2000年以来，Ron博士一直是以色列生命科学风险投资基金Israel Healthcare Ventures的创始和管理合伙人。Ron博士还是以色列生命科学风险投资基金Israel Healthcare Ventures 2 LPIncorporated（IHCV2）管理公司的首席执行官。Ron博士担任专门从事结肠直肠筛查的医疗器械公司G.I. View Ltd.和信息技术初创公司CyTwist Ltd.的董事长，并担任以下公司的董事会成员：Home Skinovations Ltd.、SipNose Ltd.、Pet Novations Ltd.、Peri-Ness Technologies Ltd.、Viroblock Ltd.、O.G.D.H. Ltd.、OrSense Ltd.和NanoPass Technologies Ltd.。此外，Ron博士担任Together Pharma Ltd.的外部董事。此外，Ron博士还担任Momentum Fund的艾瑞博德成员，Momentum Fund是特拉维夫大学技术转让研究中心的成员，也是Birad Ltd的董事会成员，Bar Ilan大学的技术转让公司，也是以色列社会金融协会预防糖尿病和结肠癌的社会影响债券科学顾问委员会的主席。Ron医生是一名医生和受过教育的律师。她拥有特拉维夫大学的医学博士和法学博士学位，并曾在特拉维夫大学工商管理学院学习。
- Hadar Ron became a director of the Company in August 2019. Since 2000, Dr. Ron has been the founding and managing partner of Israel Healthcare Ventures, an Israeli life science venture capital fund. Dr. Ron is also the chief executive officer of the management company for Israel Healthcare Ventures 2 LP Incorporated, or IHCV2, an Israeli life sciences venture capital fund. Dr. Ron serves as chairperson of G.I. View Ltd., a medical device company specializing in colorectal screenings, and CyTwist Ltd., an information technology start-up company, and as a board member of the following companies: Home Skinovations Ltd., SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Viroblock Ltd., O.G.D.H. Ltd., OrSense Ltd., and NanoPass Technologies Ltd. In addition, Dr. Ron serves as an external director of Together Pharma Ltd. In addition, Dr. Ron serves as a member of the advisory board of the Momentum Fund Tech Transfer of Tel Aviv University, a board member of BIRAD Ltd., the tech transfer company of Bar Ilan University, and is the chairperson of the scientific advisory board of Social Finance Israel's Social Impact Bond for the prevention of diabetes and colon cancer. Dr. Ron is a physician and attorney by education. She holds M.D. and L.L.B. degrees from Tel Aviv University and has studied at the School of Business Administration at Tel Aviv University.
- Moshe Mizrahy
-
Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
Moshe Mizrahy,is co-founder of InMode Ltd. (NASDAQ: INMD) and has served as its Chief Executive Officer and Chairman of its board of directors since its inception in 2008. Prior to that, Mr. Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., and is currently chairman of its board. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Santersus AG, Easy-Lap Ltd., O.B.-Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., M.N. Business Strategy Ltd., Silk'n Cure Ltd., Himalaya Family Office Advising Ltd. and Polimer Logistics (Israel) Ltd. Mr. Mizrahy is co-founder and general partner of Nitzanim AVX Kyocera Venture Capital Fund and First Israel Mezzeine Investors Fund. Mr. Mizrahy has expertise in value creation for medical technologies, fundraising, public offerings, marketing and regulatory affairs. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York. - Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
- Moshe Mizrahy,is co-founder of InMode Ltd. (NASDAQ: INMD) and has served as its Chief Executive Officer and Chairman of its board of directors since its inception in 2008. Prior to that, Mr. Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., and is currently chairman of its board. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Santersus AG, Easy-Lap Ltd., O.B.-Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., M.N. Business Strategy Ltd., Silk'n Cure Ltd., Himalaya Family Office Advising Ltd. and Polimer Logistics (Israel) Ltd. Mr. Mizrahy is co-founder and general partner of Nitzanim AVX Kyocera Venture Capital Fund and First Israel Mezzeine Investors Fund. Mr. Mizrahy has expertise in value creation for medical technologies, fundraising, public offerings, marketing and regulatory affairs. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York.
- Michael Kreindel
-
Michael Kreindel于2008年共同创立了该公司，并自成立以来一直担任我们的首席技术官。Kreindel博士于2019年8月成为公司董事。他曾于2001年至2007年担任Syneron MedicalLtd.的联合创始人和首席技术官。Kreindel博士拥有物理学和数学博士学位，也毕业于俄罗斯乌拉尔理工大学（Ural Politechnical Institute），担任实验和理论核物理的工程师和物理学家。
Michael Kreindel co-founded the Company in 2008 and has served as Inmode Ltd. Chief Technology Officer since inception. Dr. Kreindel became a director for the Company in August 2019. He previously was a co-founder of, and served as CTO of, Syneron Medical Ltd. from 2001 to 2007. Dr. Kreindel has a Ph.D. in physics and mathematics, and also graduated as an engineer and physicist in experimental and theoretical nuclear physics from Ural Politechnical Institute, Russia. - Michael Kreindel于2008年共同创立了该公司，并自成立以来一直担任我们的首席技术官。Kreindel博士于2019年8月成为公司董事。他曾于2001年至2007年担任Syneron MedicalLtd.的联合创始人和首席技术官。Kreindel博士拥有物理学和数学博士学位，也毕业于俄罗斯乌拉尔理工大学（Ural Politechnical Institute），担任实验和理论核物理的工程师和物理学家。
- Michael Kreindel co-founded the Company in 2008 and has served as Inmode Ltd. Chief Technology Officer since inception. Dr. Kreindel became a director for the Company in August 2019. He previously was a co-founder of, and served as CTO of, Syneron Medical Ltd. from 2001 to 2007. Dr. Kreindel has a Ph.D. in physics and mathematics, and also graduated as an engineer and physicist in experimental and theoretical nuclear physics from Ural Politechnical Institute, Russia.
- Bruce Mann
-
Bruce Mann于2019年8月成为公司董事。Bruce Mann是公司治理、公司法和资本市场事务方面的独立顾问和顾问，主要为新兴技术公司服务。在2017年退休之前，他曾担任Morrison&Foerster LLP的高级合伙人，合伙人或高级法律顾问30年。Mann先生一直是National Association of Securities Dealers NASD的无任所州长，也是纽约证券交易所法律咨询委员会的成员。他曾担任美国律师协会（the American Bar Association）的多种职务，包括担任ABA Business Law Section的高级律师部门、联邦监管证券委员会和风险资本和私人股本委员会的主席。Mann先生拥有威斯康星大学（University of Wisconsin）的工商管理学士学位和威斯康星大学（University of Wisconsin）法学院的法学博士学位。
Bruce Mann,Mr. Bruce Mann became a director of the Company in August 2019. Bruce Mann is an independent advisor and consultant on corporate governance, corporate law, and capital markets matters, primarily for emerging technology companies. He was a senior partner, partner, or senior of counsel of Morrison & Foerster LLP for 30 years prior to his retirement in 2017. Mr. Mann has been a Governor-at-Large of the National Association of Securities Dealers (NASD) and a member of the New York Stock Exchange Legal Advisory Committee. He has held numerous positions in the American Bar Association, including chairing the Senior Lawyers Division, the Federal Regulation of Securities Committee and the Venture Capital and Private Equity Committee of the ABA Business Law Section. Mr. Mann holds a BBA from the University of Wisconsin and a JD from the University of Wisconsin Law School. - Bruce Mann于2019年8月成为公司董事。Bruce Mann是公司治理、公司法和资本市场事务方面的独立顾问和顾问，主要为新兴技术公司服务。在2017年退休之前，他曾担任Morrison&Foerster LLP的高级合伙人，合伙人或高级法律顾问30年。Mann先生一直是National Association of Securities Dealers NASD的无任所州长，也是纽约证券交易所法律咨询委员会的成员。他曾担任美国律师协会（the American Bar Association）的多种职务，包括担任ABA Business Law Section的高级律师部门、联邦监管证券委员会和风险资本和私人股本委员会的主席。Mann先生拥有威斯康星大学（University of Wisconsin）的工商管理学士学位和威斯康星大学（University of Wisconsin）法学院的法学博士学位。
- Bruce Mann,Mr. Bruce Mann became a director of the Company in August 2019. Bruce Mann is an independent advisor and consultant on corporate governance, corporate law, and capital markets matters, primarily for emerging technology companies. He was a senior partner, partner, or senior of counsel of Morrison & Foerster LLP for 30 years prior to his retirement in 2017. Mr. Mann has been a Governor-at-Large of the National Association of Securities Dealers (NASD) and a member of the New York Stock Exchange Legal Advisory Committee. He has held numerous positions in the American Bar Association, including chairing the Senior Lawyers Division, the Federal Regulation of Securities Committee and the Venture Capital and Private Equity Committee of the ABA Business Law Section. Mr. Mann holds a BBA from the University of Wisconsin and a JD from the University of Wisconsin Law School.
- Michael Anghel
-
Michael Anghel于2019年8月成为公司董事。他自2010年起担任BiolineRx Ltd.（纳斯达克股票代码：BLRX）的董事会成员，自2010年起担任BiolineRx的投资监督委员会成员。从1977年到1999年，他领导贴现投资有限公司（IDB集团的）在技术和通信领域的活动。1999年，他创立了先进技术投资公司CAP Ventures。从2004年到2005年，他担任以色列贴现银行（TASE： DSCT）的投资银行部门DCM的首席执行官。他目前担任BiolineRx Ltd.（纳斯达克股票代码：BLRX）的董事会成员，以及Ellomay Capital Ltd.（纽约证券交易所股票代码：ELLO）的审计委员会主席和薪酬委员会主席。直到最近，他还担任the Center for Educational Technology的主席和Lahav Ltd （Tel-Aviv University Executive Program）的董事长。在开始他的商业生涯之前，他曾担任Tel Aviv大学工商管理研究生院的全职成员，在那里他教授金融和企业战略。他持有the Hebrew University（位于耶路撒冷）的经济学学士学位，以及Columbia University（位于纽约）的工商管理硕士学位和金融学博士学位。
Michael Anghel became a director of the Company in August 2019. Dr. Anghel has served on the board of directors of BiolineRx Ltd. (Nasdaq: BLRX) since 2010 and on Bioline's Investment Monitoring Committee since 2010. From 1977 to 1999, he led the Discount Investment Corporation Ltd. (of the IDB Group) activities in the fields of technology and communications. In 1999, he founded CAP Ventures, an advanced technology investment company. From 2004 to 2005, Dr. Anghel served as CEO of DCM, the investment banking arm of the Israel Discount Bank (TASE: DSCT). He currently serves on the board of directors of BiolineRx Ltd. (Nasdaq: BLRX) and as the Chairman of the Audit Committee and the Chairman of the Remuneration Committee of Ellomay Capital Ltd. (NYSE, TASE : ELLO). Until recently, he served as the chairman of the Center for Educational Technology and as the Chairman of the board of directors of Lahav Ltd (Tel-Aviv University Executive Program). Prior to launching his business career, Dr. Anghel served as a full-time member of the Graduate School of Business Administration of the Tel Aviv University, where he taught finance and corporate strategy. Dr. Anghel holds a B.A. in Economics from the Hebrew University in Jerusalem and an M.B.A. and Ph.D. in Finance from Columbia University, New York. - Michael Anghel于2019年8月成为公司董事。他自2010年起担任BiolineRx Ltd.（纳斯达克股票代码：BLRX）的董事会成员，自2010年起担任BiolineRx的投资监督委员会成员。从1977年到1999年，他领导贴现投资有限公司（IDB集团的）在技术和通信领域的活动。1999年，他创立了先进技术投资公司CAP Ventures。从2004年到2005年，他担任以色列贴现银行（TASE： DSCT）的投资银行部门DCM的首席执行官。他目前担任BiolineRx Ltd.（纳斯达克股票代码：BLRX）的董事会成员，以及Ellomay Capital Ltd.（纽约证券交易所股票代码：ELLO）的审计委员会主席和薪酬委员会主席。直到最近，他还担任the Center for Educational Technology的主席和Lahav Ltd （Tel-Aviv University Executive Program）的董事长。在开始他的商业生涯之前，他曾担任Tel Aviv大学工商管理研究生院的全职成员，在那里他教授金融和企业战略。他持有the Hebrew University（位于耶路撒冷）的经济学学士学位，以及Columbia University（位于纽约）的工商管理硕士学位和金融学博士学位。
- Michael Anghel became a director of the Company in August 2019. Dr. Anghel has served on the board of directors of BiolineRx Ltd. (Nasdaq: BLRX) since 2010 and on Bioline's Investment Monitoring Committee since 2010. From 1977 to 1999, he led the Discount Investment Corporation Ltd. (of the IDB Group) activities in the fields of technology and communications. In 1999, he founded CAP Ventures, an advanced technology investment company. From 2004 to 2005, Dr. Anghel served as CEO of DCM, the investment banking arm of the Israel Discount Bank (TASE: DSCT). He currently serves on the board of directors of BiolineRx Ltd. (Nasdaq: BLRX) and as the Chairman of the Audit Committee and the Chairman of the Remuneration Committee of Ellomay Capital Ltd. (NYSE, TASE : ELLO). Until recently, he served as the chairman of the Center for Educational Technology and as the Chairman of the board of directors of Lahav Ltd (Tel-Aviv University Executive Program). Prior to launching his business career, Dr. Anghel served as a full-time member of the Graduate School of Business Administration of the Tel Aviv University, where he taught finance and corporate strategy. Dr. Anghel holds a B.A. in Economics from the Hebrew University in Jerusalem and an M.B.A. and Ph.D. in Finance from Columbia University, New York.
高管简历
中英对照 | 中文 | 英文- Moshe Mizrahy
Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
Moshe Mizrahy,is co-founder of InMode Ltd. (NASDAQ: INMD) and has served as its Chief Executive Officer and Chairman of its board of directors since its inception in 2008. Prior to that, Mr. Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., and is currently chairman of its board. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Santersus AG, Easy-Lap Ltd., O.B.-Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., M.N. Business Strategy Ltd., Silk'n Cure Ltd., Himalaya Family Office Advising Ltd. and Polimer Logistics (Israel) Ltd. Mr. Mizrahy is co-founder and general partner of Nitzanim AVX Kyocera Venture Capital Fund and First Israel Mezzeine Investors Fund. Mr. Mizrahy has expertise in value creation for medical technologies, fundraising, public offerings, marketing and regulatory affairs. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York.- Moshe Mizrahy于2008年共同创立了该公司，自成立以来一直担任我们的首席执行官兼董事会主席。在此之前，Mizrahy先生是Syneron MedicalLtd.公司（一家位于以色列的医疗美容设备公司）的联合创始人兼首席执行官。Mizrahy先生也是Home Skinovations Ltd.的前首席执行官，该公司是一家活跃于家庭使用市场的国际医疗美容消费设备公司，目前自2007年起担任其董事会主席。除Home Skinovations Ltd.外，Mizrahy先生目前担任以下公司的董事会成员:Sipnose Ltd.、Pet Novations Ltd.、Peri-ness Technologies Ltd.、Easy-Lap Ltd、O.B.-Tools Ltd.、Urifer Ltd.、Easy Notes Ltd.、Escape Rescue Systems Ltd.、New Forest Wood Products-2012Ltd.，M.N.Business Strategy Ltd.、Himalaya Family Office Advisory Ltd.和Polimer Logistics Israel Ltd.Mizrahy先生在特拉维夫大学（Tel Aviv University）获得工程学学士学位，并在纽约佩斯大学（Pace University）获得工商管理硕士学位。
- Moshe Mizrahy,is co-founder of InMode Ltd. (NASDAQ: INMD) and has served as its Chief Executive Officer and Chairman of its board of directors since its inception in 2008. Prior to that, Mr. Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., and is currently chairman of its board. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Santersus AG, Easy-Lap Ltd., O.B.-Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., M.N. Business Strategy Ltd., Silk'n Cure Ltd., Himalaya Family Office Advising Ltd. and Polimer Logistics (Israel) Ltd. Mr. Mizrahy is co-founder and general partner of Nitzanim AVX Kyocera Venture Capital Fund and First Israel Mezzeine Investors Fund. Mr. Mizrahy has expertise in value creation for medical technologies, fundraising, public offerings, marketing and regulatory affairs. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York.
- Yair Malca
Yair Malca自2017年以来一直担任我们的首席财务官。马尔卡先生曾于2013年至2017年担任集成电路和半导体开发商Jazz Semiconductor，Inc.的财务总监。此前，他曾担任Syneron公司的总会计师（从2008年到2013年）、EZchip Semiconductor公司（网络处理器供应商）的助理总会计师（从2007年到2008年）、Bermad公司（液压控制阀供应商）的子公司总会计师（从2007年到2008年）。从2005年到2007年并从2002年到2005年在Ernst&Young开始他的公共会计职业生涯。Malca先生拥有海法大学（Haifa University）的会计与经济学学士学位和特拉维夫大学（Tel Aviv University）的工商管理硕士学位，并且是以色列的注册会计师。
Yair Malca,Yair Malca has served as Inmode Ltd. Chief Financial Officer since 2017. In his previous role, Mr. Malca was the Director of Finance for Jazz Semiconductor, Inc., a developer of integrated circuits and semiconductors, from 2013 to 2017. Before that, he served as the controller of Syneron from 2008 to 2013, as assistant controller of EZchip Semiconductor, a provider of network processors, from 2007 to 2008, as subsidiary controller of Bermad, a provider of hydraulic control valves, from 2005 to 2007, and began his career in public accounting at Ernst & Young from 2002 to 2005. Mr. Malca holds a B.A. in Accounting and Economics from Haifa University and an MBA from Tel Aviv University, and is a Certified Public Accountant in Israel.- Yair Malca自2017年以来一直担任我们的首席财务官。马尔卡先生曾于2013年至2017年担任集成电路和半导体开发商Jazz Semiconductor，Inc.的财务总监。此前，他曾担任Syneron公司的总会计师（从2008年到2013年）、EZchip Semiconductor公司（网络处理器供应商）的助理总会计师（从2007年到2008年）、Bermad公司（液压控制阀供应商）的子公司总会计师（从2007年到2008年）。从2005年到2007年并从2002年到2005年在Ernst&Young开始他的公共会计职业生涯。Malca先生拥有海法大学（Haifa University）的会计与经济学学士学位和特拉维夫大学（Tel Aviv University）的工商管理硕士学位，并且是以色列的注册会计师。
- Yair Malca,Yair Malca has served as Inmode Ltd. Chief Financial Officer since 2017. In his previous role, Mr. Malca was the Director of Finance for Jazz Semiconductor, Inc., a developer of integrated circuits and semiconductors, from 2013 to 2017. Before that, he served as the controller of Syneron from 2008 to 2013, as assistant controller of EZchip Semiconductor, a provider of network processors, from 2007 to 2008, as subsidiary controller of Bermad, a provider of hydraulic control valves, from 2005 to 2007, and began his career in public accounting at Ernst & Young from 2002 to 2005. Mr. Malca holds a B.A. in Accounting and Economics from Haifa University and an MBA from Tel Aviv University, and is a Certified Public Accountant in Israel.
- Michael Kreindel
Michael Kreindel于2008年共同创立了该公司，并自成立以来一直担任我们的首席技术官。Kreindel博士于2019年8月成为公司董事。他曾于2001年至2007年担任Syneron MedicalLtd.的联合创始人和首席技术官。Kreindel博士拥有物理学和数学博士学位，也毕业于俄罗斯乌拉尔理工大学（Ural Politechnical Institute），担任实验和理论核物理的工程师和物理学家。
Michael Kreindel co-founded the Company in 2008 and has served as Inmode Ltd. Chief Technology Officer since inception. Dr. Kreindel became a director for the Company in August 2019. He previously was a co-founder of, and served as CTO of, Syneron Medical Ltd. from 2001 to 2007. Dr. Kreindel has a Ph.D. in physics and mathematics, and also graduated as an engineer and physicist in experimental and theoretical nuclear physics from Ural Politechnical Institute, Russia.- Michael Kreindel于2008年共同创立了该公司，并自成立以来一直担任我们的首席技术官。Kreindel博士于2019年8月成为公司董事。他曾于2001年至2007年担任Syneron MedicalLtd.的联合创始人和首席技术官。Kreindel博士拥有物理学和数学博士学位，也毕业于俄罗斯乌拉尔理工大学（Ural Politechnical Institute），担任实验和理论核物理的工程师和物理学家。
- Michael Kreindel co-founded the Company in 2008 and has served as Inmode Ltd. Chief Technology Officer since inception. Dr. Kreindel became a director for the Company in August 2019. He previously was a co-founder of, and served as CTO of, Syneron Medical Ltd. from 2001 to 2007. Dr. Kreindel has a Ph.D. in physics and mathematics, and also graduated as an engineer and physicist in experimental and theoretical nuclear physics from Ural Politechnical Institute, Russia.
- Shakil Lakhani
Shakil Lakhani自2017年以来一直担任InMode&8217；北美部门总裁。在2017年8月成为公司北美总裁之前，Lakhani先生自2017年2月起担任北美销售执行Vice President，管理所有销售业务并建立了新的分销战略。他毕业于滑铁卢大学（the University of Waterloo）的工商管理学士学位，并于2006年通过加入Cynosure公司转移职业道路并进入技术领域。他曾担任Cynosure公司的多种职务，包括销售董事（从2013年9月到2017年1月）。
Shakil Lakhani,Shakil Lakhani has served as the President of InMode's North America division since 2017. Prior to becoming the President of North America for the Company in August 2017, Mr. Lakhani was previously the Executive Vice President of Sales for North America since February 2017, where he managed all sales operations and established a new distribution strategy. Mr. Lakhani previously held multiple roles at various levels at Cynosure, including Director of Sales from September 2013 through January 2017. Mr. Lakhani graduated with a B.A. from the University of Waterloo.- Shakil Lakhani自2017年以来一直担任InMode&8217；北美部门总裁。在2017年8月成为公司北美总裁之前，Lakhani先生自2017年2月起担任北美销售执行Vice President，管理所有销售业务并建立了新的分销战略。他毕业于滑铁卢大学（the University of Waterloo）的工商管理学士学位，并于2006年通过加入Cynosure公司转移职业道路并进入技术领域。他曾担任Cynosure公司的多种职务，包括销售董事（从2013年9月到2017年1月）。
- Shakil Lakhani,Shakil Lakhani has served as the President of InMode's North America division since 2017. Prior to becoming the President of North America for the Company in August 2017, Mr. Lakhani was previously the Executive Vice President of Sales for North America since February 2017, where he managed all sales operations and established a new distribution strategy. Mr. Lakhani previously held multiple roles at various levels at Cynosure, including Director of Sales from September 2013 through January 2017. Mr. Lakhani graduated with a B.A. from the University of Waterloo.